|Home | About | Journals | Submit | Contact Us | Français|
There are an estimated 350 million hepatitis B carriers worldwide. In South Africa the prevalence of monoinfection with hepatitis B has been estimated to range from 1% in urban areas to approximately 10% in rural areas. The exact prevalence of hepatitis B in the HIV-infected population has not been well established. Hepatitis B screening is not standard practice in government HIV clinics. Co-infection with hepatitis B and HIV can influence antiretroviral treatment and prognosis of both diseases. The purpose of this study was to evaluate the prevalence of hepatitis B/HIV coinfection.
This is believed to be the first prospective observational report on the prevalence of hepatitis B/HIV co-infection in South Africa. Patients on whom hepatitis B serological tests could not have been done previously were recruited from an HIV clinic in a regional hospital in Johannesburg. Standard hepatitis B serological tests were performed.
Five hundred and two participants were screened. The cohort’s average age was 37±9 years and the average CD4 count was 128 cells/μl. Twenty-four (4.8%) were hepatitis B surface antigen positive. Nearly half (47%) of the participants showed some evidence of hepatitis B exposure. The risk of hepatitis B co-infection was not significantly different when analysed in terms of sex, race, CD4 count or age. Liver function tests were not a good predictor of hepatitis B infection.
The rate of hepatitis B infection, as defined by hepatitis B surface antigen positivity, in HIV-infected individuals in urban South Africa was 5 times the rate in people who were not HIV-infected. A 5% rate of hepatitis B/HIV co-infection is a reason to increase the accessibility of tenofovir/emtricitabine (Truvada) for first-line treatment for this population.
There are an estimated 350 million hepatitis B carriers worldwide. Hepatitis B transmission is similar to that of HIV; therefore, co-infection with HIV and hepatitis B is not unusual. The prevalence of mono-infection with hepatitis B in South Africa has been estimated as approximately 10% in the rural population and 1% in urban areas.1,2 The exact prevalence of hepatitis B in the HIV population has not been accurately established.
The guidelines for the South African HIV Comprehensive Care, Management and Treatment (CCMT) programme do not include viral hepatitis studies.3 Hepatitis B serological tests are done only if serum aminotransferases are elevated in the absence of another known cause (e.g. tuberculosis and concomitant medications). We found three studies that documented the South African prevalence of HIV/HBV coinfection: a retrospective unmatched control laboratory-based study;4 a prospective study looking at HIV patients admitted to hospital;5 and a retrospective study of a cohort emanating from South African goldmines.6 The rate of co-infection varied from 6% to 17%. No prospective study has evaluated the rate of hepatitis B virus (HBV) infection in a CCMT outpatient antiretroviral (ARV) clinic in South Africa.
Lamivudine is used in the treatment of both HIV and hepatitis B7,8 and is widely used as first-line ARV therapy in most African settings. Hepatitis flares have been reported both on initiation of lamivudine and on its discontinuation in HIV-seropositive patients.9,10 Lamivudine’s safety and tolerability in HBV/HIV co-infection have not been described in resource-limited settings. Our study describing the baseline prevalence of HIV/hepatitis B co-infection in a Johannesburg CCMT clinic forms part of a PEPFAR ([USA] President’s Emergency Plan for AIDS Relief) evaluation to examine the prevalence of co-infection and the 6-month safety and tolerance of lamuvidine in this co-infected population.
Patients from an outpatient PEPFAR-supported HIV clinic in a regional academic hospital in Johannesburg were invited to participate in this study. Patients who were about to initiate ARV therapy according to the SA CCMT guidelines were informed about hepatitis B and HIV coinfection (CD4 counts <200/μl or World Health Organization (WHO) III or IV staging). A total of 502 people agreed to undergo hepatitis B screening and gave written informed consent. The study was approved by the University of the Witwatersrand ethics committee and the Saint Louis University Institutional Review Board. The patients had to be willing to start an ARV regimen containing lamivudine. Reasons given for not participating in the study included wanting additional time to listen to the education on hepatitis B or to sign consent, poor understanding of the study, not wanting an extra blood sample taken, and feeling too ill.
Serological testing included hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-HBc), hepatitis B surface antibody (anti-HBs) and hepatitis early (e) antigen HBeAg) and antibody (anti-HBe) using the Axsym assay with the MEIA methodology (Abbott Laboratories, Ill., USA). Hepatitis B viral DNA (HBV DNA) was measured using the Roche Cobas Amplicor quantitative assay (Roche Diagnostic Systems, Branchburg, NJ). Patients who were seropositive to HBsAg were considered positive, enrolled in the next phase of the study and initiated on highly active antiretroviral treatment (HAART) of lamivudine, stavudine and efavirenz, the first-line ARV regimen in the South African CCMT programme. Blood was drawn at the enrolment visit for HBeAg and anti-HBc, HBV DNA, hepatitis C and D antibody, full blood count, serum electrolytes, serum aminotransferases, urinalysis, CD4 cell count and HIV viral load.
The study comprised 502 participants, 354 (71%) females and 148 (29%) males, with a mean age (± significant deviation (SD)) of 37±9.1 years. Female subjects were significantly younger than male subjects (35.8±8.5 years v. 39.9±9.7 years, p<0.0001). The female-to-male ratio and the average age of the participants reflect the demographics of the larger clinic, which mirrors the demographic pattern of the South African HIV epidemic. The mean CD4 count was 128.6±84.4, and was similar in males and females (p>0.84). The majority (94.6%) of the 502 patients were black; the rest (27) were either coloured or white (Table I). As shown in the table, 24 (4.8%) of the 502 patients screened were seropositive for HBsAg. Fifty-three (10.5%) of the patients had isolated core antibodies without any other markers of HBV infection. Forty-seven per cent of the cohort demonstrated some exposure to hepatitis B. Only 2.6% of the cohort had serological findings consistent with vaccination (anti-HBs alone).
The risk for hepatitis B infection was not significantly different when analysed in terms of sex (odds ratio (OR) 0.7 (95% confidence interval (CI) 0.3 – 1.6), p>0.4) or racial group (OR (95% CI) 1.3 (0.2–10.1), p>0.7). There was no statistical difference in hepatitis B serological results in terms of CD4 count, age or gender, except that men were statistically more likely to have an isolated core antibody (p<0.054) (Table I) and were 1.6 times more likely to be positive overall to any hepatitis B serological test (positive for anti-HBs or anti-HBc or HBsAg combined) (OR (95% CI) 1.6 (1.1 – 2.3), p<0.012 (Table I))
Of the 24 subjects who were seropositive to HBsAg, 19 qualified for the observational study. The baseline demographics of the smaller cohort were not statistically significantly different from the main cohort in terms of mean baseline CD4 count and age.
We compared the standard laboratory results with HBeAg-negative and HBeAg-positive patients who were HBsAg positive. E antigen is thought to be a marker of hepatitis B replication. Of the 19 who were HBsAg positive, 9 were e-antigen positive (7 out of 9 had HBV DNA). Ten were e-antigen negative, and 5 of these patients had HBV DNA. There were two statistically different laboratory parameters between the e-antigen-positive and negative patients. The e-antigen-negative patients had higher CD4 counts (189.4 v. 113.11 cells/μl, p=0.0316) and higher total proteins. There were no statistical differences in HIV viral load, liver function tests or HBV viral load (although e-antigen-positive patients tended to have higher HBV viral loads) between e-antigen-positive and negative patients. None of the participants was found to be hepatitis C or D positive.
When comparing hepatitis B DNA viral load (HBV) to CD4 count or HIV viral load, there was no statistical difference. The only statistical difference was seen in a slightly higher average in the alanine transaminase (ALT) levels (mean 46±21.6) in the high detectable HBV viral loads category (Table II). However, liver function tests overall were not good predictors of hepatitis B infection. All of the 19 people who were positive for HBsAg had normal or slightly elevated serum aminotransferases (Table III).
Co-infection with HIV and hepatitis B is not well described in southern Africa, but the rate is anticipated to be high as the viruses have similar modes of transmission. Hepatitis B prevalence in the non-HIV-infected population is about 10% in rural South African areas and about 1% in urban areas.1,2 We have shown that the urban South African co-infection rate is five times that found in the non-HIV-infected population. Our serological study also demonstrates that approximately 50% of HIV-seropositive patients have been exposed to hepatitis B. The South African paediatric immunisation programme for hepatitis B started in 1995; this prevention strategy would not be reflected in this cohort.
At present, the SA CCMT guidelines do not recommend routine testing for hepatitis B co-infection. In our study, there were no other markers of hepatitis B infection, and liver function tests were not an adequate indicator of infection. This prevalence rate, determined only by surface antigen serology, may be falsely low as HBV DNA has been commonly reported in HIV-seropositive patients with isolated core antibody11 If this is the case, the prevalence of co-infection would be closer to 15% in this urban population. Real-time hepatitis B polymerase chain reaction studies on the serum of screened patients with isolated core antibody are currently being done in this cohort.
Hepatitis B can be treated with lamivudine, which is used as first-line treatment in the HIV treatment programme and is well tolerated. However, there are reports of liver complications when treating HIV/hepatitis B co-infection with the addition of antirerroviral therapy for HIV and removal of lamivudine, which can cause liver inflammation and, rarely, liver failure.10 Another complication is that lamivudine resistance also develops at a quicker rate in HIV-seropositive patients. Therefore, during the first year of lamivudine-containing ARV treatment, most patients will have adequate treatment of their hepatitis B. However, by the second year, approximately 40% of these patients will have developed resistance.9,12 The WHO guidelines recommend dual therapy in HIV patients: either tenofovir/lamivudine or tenofovir/emtricitabine (Truvada)12 to reduce the risk of developing resistance, as tenofovir also treats hepatitis B.13
Possible limitations of this study were:
What impact these complications have on ARV treatment programmes in southern Africa is unclear. Monitoring of this cohort for these complications is under way and it is hoped will provide some answers. At present, HIV patients with HBV coinfection should be monitored carefully.
The rate of co-infection with hepatitis B/HIV as defined by HBsAg is five times the rate of hepatitis B infection in the non-HIV population in urban South Africa; further investigation is necessary to evaluate the possibility of occult hepatitis B infection in patients with an isolated core antibody. A 5% prevalence of co-infection in government ARV urban clinics is a reason to consider evaluating the cost of hepatitis B serological tests, hepatitis B vaccination (50% of the cohort showed no serological exposure to hepatitis B) and initiating a tenofovir/emtricitabine backbone as an option for first-line ARV therapy in co-infected patients in government ARV clinics.
NIH/Pepfar Targeted Evaluations U01 Al-38858.
Cynthia Firnhaber, Clinical HIV Research Unit, University of the Witwatersrand, Johannesburg.
Anne Reyneke, Clinical HIV Research Unit, University of the Witwatersrand, Johannesburg.
Doreen Schulze, Clinical HIV Research Unit, University of the Witwatersrand, Johannesburg.
Babatyi Malope, Clinical HIV Research Unit, University of the Witwatersrand, Johannesburg.
Mhairi Maskew, Clinical HIV Research Unit, University of the Witwatersrand, Johannesburg.
Patrick MacPhail, Clinical HIV Research Unit, University of the Witwatersrand, Johannesburg.
Ian Sanne, Clinical HIV Research Unit, University of the Witwatersrand, Johannesburg.
Adrian Di Bisceglie, Department of Hepatology, School of Medicine, Saint Louis University, St Louis, Minn., USA.